155 related articles for article (PubMed ID: 37230222)
41. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
Gotoh M; Fujiwara Y; Yue J; Liu J; Lee S; Fells J; Uchiyama A; Murakami-Murofushi K; Kennel S; Wall J; Patil R; Gupte R; Balazs L; Miller DD; Tigyi GJ
Biochem Soc Trans; 2012 Feb; 40(1):31-6. PubMed ID: 22260662
[TBL] [Abstract][Full Text] [Related]
42. Toluene diisocyanate: Induction of the autotaxin-lysophosphatidic acid axis and its association with airways symptoms.
Broström JM; Ye ZW; Axmon A; Littorin M; Tinnerberg H; Lindh CH; Zheng H; Ghalali A; Stenius U; Jönsson BA; Högberg J
Toxicol Appl Pharmacol; 2015 Sep; 287(3):222-31. PubMed ID: 26072274
[TBL] [Abstract][Full Text] [Related]
43. MAGI-3 competes with NHERF-2 to negatively regulate LPA2 receptor signaling in colon cancer cells.
Lee SJ; Ritter SL; Zhang H; Shim H; Hall RA; Yun CC
Gastroenterology; 2011 Mar; 140(3):924-34. PubMed ID: 21134377
[TBL] [Abstract][Full Text] [Related]
44. Autotaxin/Lpar3 signaling regulates Kupffer's vesicle formation and left-right asymmetry in zebrafish.
Lai SL; Yao WL; Tsao KC; Houben AJ; Albers HM; Ovaa H; Moolenaar WH; Lee SJ
Development; 2012 Dec; 139(23):4439-48. PubMed ID: 23095890
[TBL] [Abstract][Full Text] [Related]
45. Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8
Matas-Rico E; Frijlink E; van der Haar Àvila I; Menegakis A; van Zon M; Morris AJ; Koster J; Salgado-Polo F; de Kivit S; Lança T; Mazzocca A; Johnson Z; Haanen J; Schumacher TN; Perrakis A; Verbrugge I; van den Berg JH; Borst J; Moolenaar WH
Cell Rep; 2021 Nov; 37(7):110013. PubMed ID: 34788605
[TBL] [Abstract][Full Text] [Related]
46. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.
Ma L; Uchida H; Nagai J; Inoue M; Chun J; Aoki J; Ueda H
Mol Pain; 2009 Nov; 5():64. PubMed ID: 19912636
[TBL] [Abstract][Full Text] [Related]
47. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
[TBL] [Abstract][Full Text] [Related]
48. Autotaxin and LPA receptor signaling in cancer.
Houben AJ; Moolenaar WH
Cancer Metastasis Rev; 2011 Dec; 30(3-4):557-65. PubMed ID: 22002750
[TBL] [Abstract][Full Text] [Related]
49. Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia.
Zeng Y; Kakehi Y; Nouh MA; Tsunemori H; Sugimoto M; Wu XX
Prostate; 2009 Feb; 69(3):283-92. PubMed ID: 19025891
[TBL] [Abstract][Full Text] [Related]
50. ATX and LPA receptor 3 are coordinately up-regulated in lipopolysaccharide-stimulated THP-1 cells through PKR and SPK1-mediated pathways.
Li S; Xiong C; Zhang J
FEBS Lett; 2012 Mar; 586(6):792-7. PubMed ID: 22314276
[TBL] [Abstract][Full Text] [Related]
51. Atx regulates skeletal muscle regeneration via LPAR1 and promotes hypertrophy.
Ray R; Sinha S; Aidinis V; Rai V
Cell Rep; 2021 Mar; 34(9):108809. PubMed ID: 33657371
[TBL] [Abstract][Full Text] [Related]
52. Mesenteric Adipose Tissue Contributes to Intestinal Fibrosis in Crohn's Disease Through the ATX-LPA Axis.
Huang L; Qian W; Xu Y; Guo Z; Yin Y; Guo F; Zhu W; Li Y
J Crohns Colitis; 2022 Aug; 16(7):1124-1139. PubMed ID: 35104318
[TBL] [Abstract][Full Text] [Related]
53. Different effects of lysophosphatidic acid receptor-2 (LPA
Ishimoto K; Minami A; Minami K; Ueda N; Tsujiuchi T
J Recept Signal Transduct Res; 2021 Feb; 41(1):93-98. PubMed ID: 32672083
[TBL] [Abstract][Full Text] [Related]
54. [Function and biological activities of the autotaxin-LPA axis].
Li ZW; Zhao YR; Zhao C; Fu R; Li ZY
Sheng Li Xue Bao; 2011 Dec; 63(6):601-10. PubMed ID: 22193457
[TBL] [Abstract][Full Text] [Related]
55. Mammary Adipose Tissue-Derived Lysophospholipids Promote Estrogen Receptor-Negative Mammary Epithelial Cell Proliferation.
Volden PA; Skor MN; Johnson MB; Singh P; Patel FN; McClintock MK; Brady MJ; Conzen SD
Cancer Prev Res (Phila); 2016 May; 9(5):367-78. PubMed ID: 26862086
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
57. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression.
Park SY; Jeong KJ; Panupinthu N; Yu S; Lee J; Han JW; Kim JM; Lee JS; Kang J; Park CG; Mills GB; Lee HY
Oncogene; 2011 Mar; 30(11):1351-9. PubMed ID: 21102517
[TBL] [Abstract][Full Text] [Related]
58. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
59. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.
van Meeteren LA; Ruurs P; Stortelers C; Bouwman P; van Rooijen MA; Pradère JP; Pettit TR; Wakelam MJ; Saulnier-Blache JS; Mummery CL; Moolenaar WH; Jonkers J
Mol Cell Biol; 2006 Jul; 26(13):5015-22. PubMed ID: 16782887
[TBL] [Abstract][Full Text] [Related]
60. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
